Bone density after teriparatide in patients with or without prior antiresorptive treatment: one-year results from the EUROFORS study*

References

• Stepan JJ, Alenfeld F, Boivin G, et al. Mechanisms of action of antiresorptive therapies of postmenopausal osteoporosis. Endocr Regul 2003;37:225-38
   PubMedGoogle Scholar
• Epstein S. Update of current therapeutic options for the treatment of postmenopausal osteoporosis. Clin Ther 2006;28:151-73
   PubMed Web of Science ®Google Scholar
• Cosman F. Anabolic therapy for osteoporosis: parathyroid hormone. Curr Osteoporos Rep 2005;3:143-9
   PubMedGoogle Scholar
• Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005;26:688-703
   PubMed Web of Science ®Google Scholar
• Girotra M, Rubin MR, Bilezikian JP. The use of parathyroid hormone in the treatment of osteoporosis. Rev Endocr Metab Disord 2006;7:113-21
   PubMed Web of Science ®Google Scholar
• Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348(9041):1535-41
   Web of Science ®Google Scholar
• Boivin GY, Chavassieux PM, Santora AC, et al. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 2000;27:687-94
   PubMed Web of Science ®Google Scholar
• Borah B, Dufresne TE, Chmielewski PA, et al. Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone 2004;34:736-46
   PubMed Web of Science ®Google Scholar
• Ma YL, Zeng Q, Donley DW, et al. Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis. J Bone Miner Res 2006;21:855-64
   PubMed Web of Science ®Google Scholar
• McClung MR, San Martin J, Miller PD, et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 2005;165:1762-8
   PubMed Web of Science ®Google Scholar
• Arlot M, Meunier PJ, Boivin G, et al. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res 2005;20:1244-53
   PubMed Web of Science ®Google Scholar
• Jiang Y, Zhao JJ, Mitlak BH, et al. Recombinant human parathyroid hormone (1–34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 2003;18:1932-41
   PubMed Web of Science ®Google Scholar
• Dempster DW, Cosman F, Kurland ES, et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Miner Res 2001;16:1846-53
   PubMed Web of Science ®Google Scholar
• Zanchetta JR, Bogado CE, Ferretti JL, et al. Effects of teriparatide [recombinant human parathyroid hormone (1–34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 2003;18:539-43
   PubMed Web of Science ®Google Scholar
• Uusi-Rasi K, Semanick LM, Zanchetta JR, et al. Effects of teriparatide [rhPTH (1–34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women. Bone 2005;36:948-58
   PubMed Web of Science ®Google Scholar
• Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41
   PubMed Web of Science ®Google Scholar
• Lindsay R, Scheele WH, Neer R, et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 2004;164:2024-30
   PubMed Web of Science ®Google Scholar
• Prince R, Sipos A, Hossain A, et al. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 2005;20:1507-13
   PubMed Web of Science ®Google Scholar
• Vahle JL, Sato M, Long GG, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1–34) for 2 years and relevance to human safety. Toxicol Pathol 2002;30:312-21
   PubMed Web of Science ®Google Scholar
• Vahle JL, Long GG, Sandusky G, et al. Bone neoplasms in F344 rats given teriparatide [rhPTH(1–34)] are dependent on duration of treatment and dose. Toxicol Pathol 2004;32:426-38
   PubMed Web of Science ®Google Scholar
• Boonen S, Marin F, Obermayer-Pietsch B, et al. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2008;93:852-60
   PubMed Web of Science ®Google Scholar
• Obermayer-Pietsch BM, Marin F, McCloskey EV, et al. Effects of two years of daily teriparatide treatment on bone mineral density in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res 2008; published online 27 May 2008; doi:10.1359/jbmr.080506
   Google Scholar
• Genant HK, Grampp S, Gluer CC, et al. Universal standardization for dual X-ray absorptiometry: patient and phantom cross-calibration results. J Bone Miner Res 1994;9:1503-14
   PubMed Web of Science ®Google Scholar
• Hanson J. Standardization of femur BMD. J Bone Miner Res 1997;12:1316-7
   PubMed Web of Science ®Google Scholar
• Marcus R, Wang O, Satterwhite J, et al. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 2003;18:18-23
   PubMed Web of Science ®Google Scholar
• Ettinger B, San Martin J, Crans G, et al. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004;19:745-51
   PubMed Web of Science ®Google Scholar
• Bauer DC, Garnero P, Bilezikian JP, et al. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2006;91:1370-75
   PubMed Web of Science ®Google Scholar
• Gallagher JC, Rosen CJ, Chen P, et al. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis. Bone 2006;39:1268-75
   PubMed Web of Science ®Google Scholar
• Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003;349:1207-15
   PubMed Web of Science ®Google Scholar
• Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis. N Engl J Med 2005;353:555-65
   PubMed Web of Science ®Google Scholar
• Graeff C, Timm W, Nickelsen TN, et al. Monitoring teriparatide-associated changes in vertebral microstructure by high-resolution CT in vivo: results from the EUROFORS study. J Bone Miner Res 2007;22:1426-33
   PubMed Web of Science ®Google Scholar
• Jakob F, Marin F, Martin-Mola E, et al. Characterization of patients with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO). QJM 2006;99:531-43
   PubMed Web of Science ®Google Scholar
• Adami S, Isaia G, Luisetto G, et al. Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study. J Bone Miner Res 2006;21:1565-70
   PubMed Web of Science ®Google Scholar
• Díez-Pérez A, González-Macías J. Inadequate responders to osteoporosis treatment: proposal for an operational definition. Osteoporos Int 2008; June 11 (epub ahead of print)
   Google Scholar
• Cosman F, Nieves J, Zion M, et al. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 2005;353(6):566-75
   Web of Science ®Google Scholar
• Orwoll E, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone mineral density in men with osteoporosis. J Bone Miner Res 2003;18(1):9-17
   Web of Science ®Google Scholar